Go Pro

Brainstorm Cell Therapeutics (BCLI) Earnings Date, Estimates & Call Transcripts

Brainstorm Cell Therapeutics logo
$1.12 0.00 (0.00%)
As of 08/28/2026 03:55 PM Eastern

Brainstorm Cell Therapeutics Earnings Summary

Brainstorm Cell Therapeutics issued Q2 2026 earnings on August 14, 2026, reporting an EPS of -$0.35, which missed the consensus estimate of -$0.29 by $0.06. With a trailing EPS of -$1.65, Brainstorm Cell Therapeutics' earnings are expected to grow next year, from ($3.01) to ($1.60) per share.

Upcoming Q3
Earnings Date
Nov. 16Before Market OpensEstimated
Consensus EPS
(Aug. 14)
-$0.29
Actual EPS
(Aug. 14)
-$0.35 Missed By -$0.06

Q2 2026 Earnings Resources

BCLI Upcoming Earnings

Brainstorm Cell Therapeutics' next earnings date is estimated for Monday, November 16, 2026, based on past reporting schedules.

Get Brainstorm Cell Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Brainstorm Cell Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

BCLI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Brainstorm Cell Therapeutics Analyst EPS Estimates

Current Year EPS Consensus Estimate
($3.01) EPS
Next Year EPS Consensus Estimate
($1.60) EPS

Brainstorm Cell Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/16/2026
(Estimated)
--------
8/14/2026--$0.29-$0.35 -$0.06---
5/15/2025Q1 2025-$0.38-$0.45 -$0.07-$0.45--

Brainstorm Cell Therapeutics Earnings - Frequently Asked Questions

Brainstorm Cell Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 16th, 2026 based off last year's report dates. Learn more on BCLI's earnings history.

In the previous quarter, Brainstorm Cell Therapeutics (NASDAQ:BCLI) missed the analysts' consensus estimate of ($0.29) by $0.06 with a reported earnings per share (EPS) of ($0.35). Learn more on analysts' earnings estimate vs. BCLI's actual earnings.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) has a recorded net income of -$11.62 million. BCLI has generated -$1.65 earnings per share over the last four quarters.

Brainstorm Cell Therapeutics' earnings are expected to grow from ($3.01) per share to ($1.60) per share in the next year.


Earnings data for NASDAQ:BCLI is sourced from Fiscal.ai, with the most recent quarter reported on 8/14/2026. New results are added as companies report their earnings.
From Our Partners